دانلود کتاب Pharmaceuticals for Targeting Coronaviruses

فهرست مطالب :

Cover
Title
Copyright
End User License Agreement
Contents
Preface
REFERENCES
List of Contributors
Structure-Based Drug Discovery Approaches Applied to SARS-CoV-2 (COVID-19)
Igor José dos Santos Nascimento1, Thiago Mendonça de Aquino1 and Edeildo Ferreira da Silva-Júnior1,2,*
1. INTRODUCTION
2. CORONAVIRUSES: HISTORY AND STRUCTURE
3. DRUG DISCOVERY PROCESS
4. SBDD STRATEGIES AND DISCOVERY OF HITS AGAINST CORONAVIRUSES
4.1. Homology Modeling
4.2. Pharmacophore Modeling
4.3. Molecular Docking and Dynamics Simulations
4.4. Fragment-Based Drug Discovery
4.5. De Novo Drug Discovery
4.5. Virtual Screening (VS) and Virtual High-throughput screening (vHTS)
5. CHALLENGES IN SBDD FOR SARS-COV-2
CONCLUSION
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGMENTS
REFERENCES
Potential Antiviral Medicinal Plants against Novel SARS-CoV-2 and COVID-19 Outbreak
Nazim Sekeroglu1,2,* and Sevgi Gezici2,3
1. INTRODUCTION
2. MEDICINAL PLANT-BASED ANTIVIRAL THERAPEUTICS
2.1. Rockrose (Cistus spp.)
2.2. Lemon balm (Melissa Officinalis L.)
2.3. Rosemary (Rosmarinus Officinalis L.)
2.4. Olive leaf (Olea Europea L.)
2.5. Thyme Species (Origanum, Thymus & Thymbra)
2.6. Licorice Root (Glycyrrhiza Glabra L.)
2.7. Other Antiviral Medicinal Plants
CONCLUSION AND FUTURE DIRECTIONS
LIST OF ABBREVIATIONS
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Infections Caused by SARS: Main Characteristics, Targets and Inhibitors
Herbert Igor Rodrigues de Medeiros1, Gabriela Cristina Soares Rodrigues1, Mayara dos Santos Maia1, Marcus Tullius Scotti1 and Luciana Scotti1,*
1. INTRODUCTION
2. ORIGIN AND EPIDEMIOLOGY
3. SARS PATHOGENESIS
4. TAXONOMY
5. MAIN TARGETS OF SARS-COV AND SARS-COV-2
5.1. Glycoprotein Spike (S)
5.2. Membrane Protein (M)
5.3. Envelope Protein (E)
5.4. Nucleocapsid Protein (N)
5.5. 3-chymotrypsin-like Cysteine Protease (3CLpro)
5.6. Angiotensin Converting Enzyme (ACE)-2
6. DRUGS AND INHIBITORS AGAINST SARS
CONCLUSION
LIST OF ABBREVIATIONS
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Natural Sourced Traditional Indian and Chinese Medicines to Combat COVID-19
Mayank Kumar Khede1, Anil Kumar Saxena2,* and Sisir Nandi2,*
1. INTRODUCTION TO INDIAN AND CHINESE TRADITIONAL MEDICINE
2. TRADITIONAL DRUGS AND NATURAL SOURCED FORMULATION FOR TREATMENT OF COVID-19
2.1. Traditional Indian Medicines (TIM) to Combat COVID-19
2.2. Traditional Chinese Medicine (TCM) To Combat COVID-19
CONCLUSION
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Peptidomimetic and Peptide-Derived Against 3CLpro from Coronaviruses
Paulo Fernando da Silva Santos-Júnior1, João Xavier de Araújo-Júnior2 and Edeildo Ferreira da Silva-Júnior1,2,*
1. INTRODUCTION
2. CHEMISTRY ASPECTS OF PEPTIDOMIMETICS
3. BIOCHEMISTRY ASPECTS AND MOLECULAR HOMOLOGY OF 3CLPRO FROM MERS-COV, SARS-COV, AND SARS-COV-2
3.1. Structure, Function, and Druggability of 3CLpro from Coronaviruses
3.2. Catalytic Site of 3CLpro from Coronaviruses
4. CORONAVIRUSES 3CLPRO AND THEIR INHIBITORS
4.1. Warhead Groups
4.2. Peptidomimetics Containing Michael Acceptors as Warhead Groups
4.3. Peptidomimetics Containing Aldehydes as Warhead Groups
4.4. Peptidomimetics Containing Keto Groups as Warheads
4.4.1. Fluoromethyl Ketone Group
4.4.2. 1,4-Peptidomimetics Containing Phthalazinediones as Warhead Groups
4.4.3. Peptidomimetics Containing Benzothiazolones/thiazolones as Warhead Groups
4.4.4. Peptidomimetics Containing α-ketoamides as Warhead Groups
4.4.5. Peptidomimetics Containing Nitroanilides as Warhead Groups
4.5. Peptidomimetics Containing Nitriles as Warhead Groups
4.6. Peptidomimetics Containing Aza-epoxides and Aziridines as Warhead Groups
5. DRUG REPURPOSING FOR PEPTIDOMIMETICS
6. FINAL CONSIDERATIONS AND FUTURE OUTLOOK
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Subject Index
Back Cover